Show notes
Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa…
Website: shows.acast.com

